Quarterly report pursuant to Section 13 or 15(d)

2. Liquidity and Financial Condition (Details Narrative)

v3.20.4
2. Liquidity and Financial Condition (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Jun. 24, 2020
May 02, 2020
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2020
Dec. 31, 2019
Mar. 31, 2020
Net loss     $ (650,000) $ (1,084,000) $ (290,000) $ (1,572,000)  
Accumulated deficit     (172,536,000)   (172,536,000)   $ (172,246,000)
Working capital     $ 12,329,000   12,329,000   $ 7,518,000
Cash received from sale of Micromed         610,000    
Proceeds from exercise of stock options         451,000    
Proceeds from exercise of warrants         1,759,000    
Asset Purchase Agreement [Member]              
Aggregate sale price of Micromed division $ 850,000            
Cash received from sale of Micromed 610,000            
Credit received for future testing services from sale of Micromed 100,000            
Sale of assets, amount held in escrow 60,000            
Accounts receivable remaining from sale of asset $ 81,000            
Paycheck Protection Program [Member] | States Bank in Atlanta [Member]              
Proceeds from loan   $ 1,310,000     $ 1,310,000    
Loan interest rate   1.00%     1.00%    
Loan maturity date   Apr. 29, 2022     Apr. 29, 2022    
Forgiveness of loan   $ 930,000